Circulating tumor cells as prognostic markers in neuroendocrine tumors

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 365-372

  Khan, Mohid S ^a,b   Kirkwood, Amy ^c   Tsigani, Theodora ^a   Garcia Hernandez, Jorge ^b   Hartley, John A ^a   Caplin, Martyn E ^b   Meyer, Tim ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; FEMALE; HUMAN; IMMUNOMAGNETIC SEPARATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CELL SEPARATION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NEUROENDOCRINE TUMORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873374248     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.2905     Document Type: Article

References (35)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
2. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
3. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
4. Rindi G, Kloppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 451:757-762, 2007 (Pubitemid 47497934)
5. Rindi G, Klöppel G, Alhman H, et al: TNM staging of foregut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 449:395-401, 2006 (Pubitemid 44451313)
6. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
7. Turner NC, Strauss SJ, Sarker D, et al: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102:1106-1112, 2010
8. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
9. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-1430, 2005
10. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004 (Pubitemid 39095313)
11. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213-3221, 2008
12. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
13. Khan MS, Tsigani T, Rashid M, et al: Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res 17:337-345, 2011
14. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
15. Hayes DF, Cristofanilli M, Budd GT, et al: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218-4224, 2006
16. Budd GT, Cristofanilli M, Ellis MJ, et al: Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403-6409, 2006 (Pubitemid 44799711)
17. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004 (Pubitemid 39383039)
18. Altman DG, Vergouwe Y, Royston P, et al: Prognosis and prognostic research: Validating a prognostic model. BMJ 338:b605, 2009
19. Yao JC, Pavel M, Phan AT, et al: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96:3741-3749, 2011
20. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
21. Raffel A, Eisenberger CF, Cupisti K, et al: Increased EpCAM expression in malignant insulinoma: Potential clinical implications. Eur J Endocrinol 162:391-398, 2010
22. Spizzo G, Fong D, Wurm M, et al: EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis. J Clin Pathol 64:415-420, 2011
23. Krebs MG, Hou JM, Sloane R, et al: Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7:306-315, 2012
24. Cohen SJ, Punt CJ, Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20:1223-1229, 2009
25. Lucci A, Hall CS, Lodhi AK, et al: Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 13:688-695, 2012
26. Modlin IM, Gustafsson BI, Moss SF, et al: Chromogranin A: Biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 17:2427-2443, 2010
27. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009
28. Kirby BJ, Jodari M, Loftus MS, et al: Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One 7:e35976, 2012
29. Strati A, Markou A, Parisi C, et al: Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 11:422, 2011
30. Markou A, Strati A, Malamos N, et al: Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 57:421-430, 2011
31. Xu X, Hou Y, Yin X, et al: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148:886-895, 2012
32. Hou Y, Song L, Zhu P, et al: Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148:873-885, 2012
33. Navin N, Kendall J, Troge J, et al: Tumour evolution inferred by single-cell sequencing. Nature 472:90-94, 2011
34. Vona G, Sabile A, Louha M, et al: Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156:57-63, 2000 (Pubitemid 30644439)
35. Talasaz AH, Powell AA, Huber DE, et al: Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106:3970-3975, 2009